NKTX Share Price Performance
US$2.54
0.19 (8.09%)
Price US$2.54
Share Pricen/a
Nkarta, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
NKTX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Nkarta, Inc. Key Details
About NKTX
- Founded
- 2015
- Employees
- 105
- CEO
- WebsiteView website
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
